Want to see AU:OPT full AI Analyst Report?
Top Page
Opthea
(Sydney:OPT)
Select Model
Select Model
Rating:39Underperform
Price Target:
AU$0.01
▼(-98.00% Downside)
Action:Downgraded
Date:06/05/26
The score is weighed down primarily by weak financial performance (minimal/volatile revenue, large recurring losses, and heavy ongoing cash burn with negative equity) and very weak technical momentum signals. Valuation contributes limited support due to negative earnings and no stated dividend yield.
Positive Factors
Differentiated lead candidate (sozinibercept)
Sozinibercept’s distinct mechanism (VEGF-C/D inhibition) complements anti-VEGF-A therapy and represents a durable scientific differentiation. If clinical success is achieved, this could materially expand treatment efficacy, support combination-label strategies, and attract long-term partnerships or licensing given complementary mode of action.
Negative Factors
Persistent heavy cash burn
Sustained operating cash outflows of ~-159M per year indicate chronic negative cash generation and a reliance on external funding. Over multiple quarters this creates dilution risk, constrains strategic flexibility, and makes long-term program completion contingent on successful financings or partnerships.
Read all positive and negative factors
Positive Factors
Negative Factors
Differentiated lead candidate (sozinibercept)
Sozinibercept’s distinct mechanism (VEGF-C/D inhibition) complements anti-VEGF-A therapy and represents a durable scientific differentiation. If clinical success is achieved, this could materially expand treatment efficacy, support combination-label strategies, and attract long-term partnerships or licensing given complementary mode of action.
Read all positive factors
Opthea (OPT) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$20.52M
Dividend YieldN/A
Average Volume (3M)0.00
Price to Earnings (P/E)2.9
Beta (1Y)2.06
Revenue Growth-98.07%
EPS GrowthN/A
CountryAU
Employees33
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.14
Shares Outstanding1,367,978,100
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.07
Price to Book (P/B)-3.65
Price to Sales (P/S)29392.74
P/FCF Ratio-4.63
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)>-0.01
Revenue Forecast (FY)AU$200.00K
Opthea Business Overview & Revenue Model
Company Description
Opthea Limited is an Australian clinical-stage biopharmaceutical company focused on developing and commercializing therapies primarily for eye diseases. The foundation of its development efforts lies in its intellectual property portfolio, which t...
How the Company Makes Money
null...
Opthea Financial Statement Overview
Summary
Income Statement
8
Very Negative
Balance Sheet
18
Very Negative
Cash Flow
10
Very Negative
| Breakdown | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 25.00K | 124.67K | 108.00K | 125.05K | 91.98K |
| Gross Profit | 25.00K | 124.67K | -89.31K | -107.42K | -360.29K |
| EBITDA | -123.19M | -199.29M | -134.88M | -99.01M | -50.14M |
| Net Income | -162.79M | -220.24M | -211.88M | -127.99M | -60.79M |
Balance Sheet | |||||
| Total Assets | 56.80M | 188.79M | 148.19M | 87.32M | 184.36M |
| Cash, Cash Equivalents and Short-Term Investments | 48.44M | 172.47M | 133.99M | 44.63M | 118.19M |
| Total Debt | 376.89M | 141.65M | 85.84M | 0.00 | 112.97K |
| Total Liabilities | 257.87M | 264.60M | 156.98M | 17.55M | 4.16M |
| Stockholders Equity | -201.07M | -75.81M | -8.79M | 69.77M | 180.20M |
Cash Flow | |||||
| Free Cash Flow | -158.66M | -161.05M | -179.34M | -98.39M | -61.08M |
| Operating Cash Flow | -158.64M | -161.02M | -179.30M | -98.37M | -61.06M |
| Investing Cash Flow | -13.00K | -33.49K | -32.64K | -16.91K | 656.48K |
| Financing Cash Flow | 34.77M | 243.73M | 167.28M | 171.60K | 116.94M |
Opthea Technical Analysis
Negative
0.60
Price Trends
0.35
Negative
0.48
Negative
0.54
Negative
Market Momentum
-0.10
Negative
2.93
Positive
66.67
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:OPT, the sentiment is Negative. The current price of 0.6 is above the 20-day moving average (MA) of 0.01, above the 50-day MA of 0.35, and above the 200-day MA of 0.54, indicating a neutral trend. The MACD of -0.10 indicates Negative momentum. The RSI at 2.93 is Positive, neither overbought nor oversold. The STOCH value of 66.67 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:OPT.
Opthea Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
57 Neutral | AU$4.92B | ― | -1.72% | ― | 59.13% | -121.52% | |
52 Neutral | AU$2.65B | -19.07 | -14.02% | ― | 1069.25% | 18.67% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
45 Neutral | AU$802.12M | -7.61 | -59.59% | ― | ― | -70.72% | |
41 Neutral | AU$3.41M | -0.38 | -179.37% | ― | ― | 24.59% | |
41 Neutral | AU$112.24M | -3.31 | 279.21% | ― | ― | -37.23% | |
39 Underperform | AU$20.52M | 2.86 | 44.23% | ― | -98.07% | ― |
* Healthcare Sector Average
AU:OPT
Opthea
0.02
-0.59
-97.50%
AU:CYP
Cynata Therapeutics Limited
0.01
-0.15
-91.25%
AU:MSB
Mesoblast Limited
2.05
0.42
25.77%
AU:TLX
Telix Pharmaceuticals
17.18
-7.01
-28.98%
AU:CU6
Clarity Pharmaceuticals Ltd.
2.15
-0.79
-26.87%
AU:RCE
Recce Pharmaceuticals Ltd.
0.38
0.07
22.95%
Opthea Corporate Events
Opthea Director Jeremy Levin Boosts Stake With New Options and Share Purchase
Jun 24, 2026
Opthea director Jeremy Levin has significantly increased his equity exposure through a combination of newly issued options and on-market share purchases. The move underscores the company’s ongoing reliance on stock-based incentives to retain...
JAF Capital exits substantial holding in Opthea
Jun 22, 2026
JAF Capital Pty Ltd has ceased to be a substantial shareholder in Opthea Limited after selling its holdings on market over several days in June 2026. The disposals, totaling more than 31 million fully paid ordinary shares, reduce concentrated owne...
Opthea director Katherine Connell increases shareholding with on‑market purchase
Jun 19, 2026
Opthea director Katherine Connell has increased her stake in the company through an on‑market purchase of 2 million ordinary shares at $0.015 per share, for a total consideration of $30,000. The transaction, dated 15 June 2026, lifts her hol...
BNY Mellon Group Exits Substantial Shareholding in Opthea
Jun 17, 2026
The Bank of New York Mellon Corporation and its related entities have notified Opthea that they have ceased to be substantial shareholders in the company as of 16 June 2026. This reduction in ownership alters Opthea’s institutional sharehold...
Opthea Schedules Online Market Update for Investors
Jun 9, 2026
Opthea Limited announced it will deliver a corporate market update on 12 June 2026, led by Executive Chair Jeremy Levin via an online webinar for analysts and investors. The scheduled update, supported by pre-registered conference call and live au...
Opthea relaunches on ASX with rare lung disease push for OPT-302
Jun 2, 2026
Opthea will be reinstated to trading on the ASX as it relaunches with a sharpened strategy built around advancing its VEGF-C/VEGF-D inhibitor OPT-302 for lymphangioleiomyomatosis, a rare, debilitating lung disease that primarily affects women and ...
Opthea calls virtual extraordinary general meeting for July 2026
Jun 2, 2026
Opthea Limited has scheduled an extraordinary general meeting to be held virtually on 3 July 2026 at 10:00 a.m. Melbourne time, allowing shareholders to participate online. The company has circulated the notice of meeting, explanatory notes and pr...
ASX Flags Delisting Risk for Long-Term Suspended Companies Over Reporting Delays
Apr 17, 2026
The Australian Securities Exchange has released an update on long-term suspended entities, listing companies whose securities have been halted from trading for more than three months and detailing their outstanding financial reporting obligations....
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.